Archived Webinars

 

Archived Webinars

As our industry shifts importance from volume to value, it is more important than ever to have a strategic approach to collecting and analyzing evidence. UBC offers a robust history of building economic evidence to demonstrate and support the value of products on behalf of...

Generating real-world evidence is essential to uncovering the potential effects a product may have on pregnancy outcomes, particularly for women of childbearing age who require chronic therapy for diabetes, depression, epilepsy, asthma and more.

Understanding key...

Nearly half of clinical trial study sites don’t meet enrollment requirements or fail to enroll a single patient. This contributes to extended study timelines and increased competition for high-performing study sites. Proactively preparing sites before the site activation...

Patient-centric medicine is not a passing fad. New technology trends, healthcare laws, and diverse therapeutic options are converging to provide patients even more opportunities to be proactively engaged in their health journeys. Patients are becoming increasingly educated on...

Sponsors today are challenged to properly evaluate the effectiveness of their risk minimisation activities in Europe. European Directive 2001/83/EC requires that the market authorisation holder shall “monitor the outcome of risk minimisation measures which are contained in...

Rising R&D costs and a shift toward patient empowerment are converging forces that are changing the face of clinical research. It is critical to design and implement clinical trials that minimize cost and leverage patient engagement.

Erem Latif, Trial Enhancement...

Payer and regulatory evidence requirements are converging, resulting in both opportunities and challenges for real-world study designs. European pharmacovigilance legislation was revised in July 2012, defining Post-Authorization Safety Study (PASS) requirements and presenting...

To be best prepared for postapproval safety monitoring, evaluation, and mitigation, biopharmaceutical companies must know what is required in terms of an RMP and a REMS. Preparation of these tools must begin during drug development. Postapproval safety is not just a...

Pharmaceutical manufacturers are accustomed to establishing robust procedures and systems to support compliance with the pharmacovigilance regulations set forth by regulatory bodies around the globe.  Pharmacies on the other hand have traditionally followed local state...

Regulators, payers, providers, HTA agencies and other healthcare stakeholders are increasingly recognizing the importance of observational data from patient registries and related research studies.  Observational studies can be used to help sponsors and the varied...

This webinar addresses the key implications of healthcare reform and how states plan to address the Affordable Care Act.  With 60 provisions of the ACA already implemented many of the remaining provisions will have the greatest impact on Patients Assistance Programs....

This webcast provides insights to how nursing services are being utilized by pharmaceutical manufacturers to increase patient education about their therapy and interact with prescribers in order to maximize therapy adherence.  A broad base of nursing resources are...

If there are no “one size fits all” risk management strategies in the EU, how are manufacturers successfully navigating multiple regulatory agencies and healthcare systems to implement programs across the continent?   Janine Collins, M.D., Senior Director, European...

In the absence of available medical claims or other databases, retrospective chart review designs can be leveraged to support the gathering of real-world data appropriate for evaluations of burden of illness, drug utilization and safety outcomes.  Data collected from...